Chronic Pain – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sat, 26 Aug 2023 15:38:17 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Chronic Pain – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 An answered call for aid? Cannabinoid clinical framework for the opioid epidemic https://www.cannabisclinicians.org/2023/08/26/an-answered-call-for-aid-cannabinoid-clinical-framework-for-the-opioid-epidemic/ Sat, 26 Aug 2023 15:38:17 +0000 https://www.cannabisclinicians.org/?p=29117 The opioid crisis continues in full force, as physicians and caregivers are desperate for resources to help patients with opioid use and chronic pain disorders find safer and more accessible non-opioid tools.

Main body
The purpose of this article is to review the current state of the opioid epidemic; the shifting picture of cannabinoids; and the research, policy, and current events that make opioid risk reduction an urgent public health challenge. The provided table contains an evidence-based clinical framework for the utilization of cannabinoids to treat patients with chronic pain who are dependent on opioids, seeking alternatives to opioids, and tapering opioids.

The post An answered call for aid? Cannabinoid clinical framework for the opioid epidemic appeared first on Society of Cannabis Clinicians.

]]> Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: Real-world evidence from Project Twenty21 https://www.cannabisclinicians.org/2023/05/06/characteristics-of-and-3-month-health-outcomes-for-people-seeking-treatment-with-prescribed-cannabis-real-world-evidence-from-project-twenty21/ Sun, 07 May 2023 02:31:18 +0000 https://www.cannabisclinicians.org/?p=28561 Medicinal cannabis has been legal in the UK since 2018 but there is limited information about characteristics of people seeking prescribed cannabis and the effectiveness of this treatment. This paper documents symptom patterns and quality of life among individuals seeking medicinal cannabis and examines changes in symptoms, quality of life and use of pre- scribed opioids using data from an observational registry study of patients (Project Twenty21). Self-report data, including condition-specific symptomatology and general health (quality of life, general health, mood and sleep), were available at treatment entry for 2833 patients seeking medicinal cannabis for any indication and also at 3-month follow-up for 1410 individuals seeking treatment for anxiety disorders, chronic pain or PTSD. Among chronic pain patients, dose and fre- quency of prescribed opioid use was available.

The post Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: Real-world evidence from Project Twenty21 appeared first on Society of Cannabis Clinicians.

]]> Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions https://www.cannabisclinicians.org/2023/04/16/clinical-practice-guidelines-for-cannabis-and-cannabinoid-based-medicines-in-the-management-of-chronic-pain-and-co-occurring-conditions/ Sun, 16 Apr 2023 14:11:15 +0000 https://www.cannabisclinicians.org/?p=28353 The interest in the pharmacological applications of cannabinoids is largely increasing in a wide range of medical areas. Recently, research on its potential role in eye conditions, many of which are chronic and/or disabling and in need of new alternative treatments, has intensified. However, due to cannabinoids’ unfavorable physicochemical properties and adverse systemic effects, along with ocular biological barriers to local drug administration, drug delivery systems are needed. Hence, this review focused on the following: (i) identifying eye disease conditions potentially subject to treatment with cannabinoids and their pharmacological role, with emphasis on glaucoma, uveitis, diabetic retinopathy, keratitis and the prevention of Pseudomonas aeruginosa infections; (ii) reviewing the physicochemical properties of formulations that must be controlled and/or optimized for successful ocular administration; (iii) analyzing works evaluating cannabinoid-based formulations for ocular administration, with emphasis on results and limitations; and (iv) identifying alternative cannabinoid- based formulations that could potentially be useful for ocular administration strategies. Finally, an overview of the current advances and limitations in the field, the technological challenges to overcome and the prospective further developments, is provided.

The post Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions appeared first on Society of Cannabis Clinicians.

]]> Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks https://www.cannabisclinicians.org/2023/03/04/cannabinoids-as-a-potential-alternative-to-opioids-in-the-management-of-various-pain-subtypes-benefits-limitations-and-risks/ Sun, 05 Mar 2023 02:42:40 +0000 https://www.cannabisclinicians.org/?p=27954 Pain is a global phenomenon encompassing many subtypes that include neuropathic, musculoskeletal, acute postoperative, cancer, and geriatric pain. Traditionally, opioids have been a mainstay pharmacological agent for managing many types of pain. However, opioids have been a subject of controversy with increased addiction, fatality rates, and cost burden on the US healthcare system. Cannabinoids have emerged as a potentially favorable alternative or adjunctive treatment for various types of acute and chronic pain. This narrative review seeks to describe the efficacy, risks, and benefits of cannabinoids as an adjunct or even potential replacement for opioids in the treatment of various subtypes of pain.

The post Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks appeared first on Society of Cannabis Clinicians.

]]> Cannabis and cannabinoid medications for the treatment of chronic orofacial pain: A scoping review https://www.cannabisclinicians.org/2023/01/21/cannabis-and-cannabinoid-medications-for-the-treatment-of-chronic-orofacial-pain-a-scoping-review-2/ Sun, 22 Jan 2023 00:51:21 +0000 https://www.cannabisclinicians.org/?p=27556 To collate and summarize existing evidence for the use of cannabis and cannabinoids to treat chronic orofacial pain (COP) by oral and maxillofacial surgeons (OMFS), oral medicine specialists (OMS), and orofacial pain specialists (OPS). We systematically screened for sources including a measure of effect of a cannabinoid compound on pain in COP patients that might be treated by our target specialists. Sources were selected by two authors independently. Sources were summarized by country, publication date, objective(s), COP condition(s) studied, cannabinoid(s) studied, methods, results, limitations, and conclusions. A thematic analysis and word cloud were conducted to elucidate commonalities, emphases, and gaps amongst identified sources.

The post Cannabis and cannabinoid medications for the treatment of chronic orofacial pain: A scoping review appeared first on Society of Cannabis Clinicians.

]]> Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment https://www.cannabisclinicians.org/2023/01/13/role-of-the-endocannabinoid-system-in-fragile-x-syndrome-potential-mechanisms-for-benefit-from-cannabidiol-treatment/ Fri, 13 Jan 2023 23:07:18 +0000 https://www.cannabisclinicians.org/?p=27462 Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive function and in the pathogenesis of fragile X syndrome (FXS). This review describes the ECS, its role in the central nervous system, how it is dysregulated in FXS, and the potential role of cannabidiol as a treatment for FXS. FXS is caused by deficiency or absence of the fragile X messenger ribonucleoprotein 1 (FMR1) protein, FMRP, typically due to the presence of >200 cytosine, guanine, guanine sequence repeats leading to methylation of the FMR1 gene promoter.

The post Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment appeared first on Society of Cannabis Clinicians.

]]> Cannabis and Cannabinoid Medications for the Treatment of Chronic Orofacial Pain: A Scoping Review https://www.cannabisclinicians.org/2023/01/13/cannabis-and-cannabinoid-medications-for-the-treatment-of-chronic-orofacial-pain-a-scoping-review/ Fri, 13 Jan 2023 22:50:31 +0000 https://www.cannabisclinicians.org/?p=27459 We systematically screened for sources including a measure of effect of a cannabinoid compound on pain in COP patients that might be treated by our target specialists. Sources were selected by two authors independently. Sources were summarized by country, publication date, objective(s), COP condition(s) studied, cannabinoid(s) studied, methods, results, limitations, and conclusions. A thematic analysis and word cloud were conducted to elucidate commonalities, emphases, and gaps amongst identified sources.

The post Cannabis and Cannabinoid Medications for the Treatment of Chronic Orofacial Pain: A Scoping Review appeared first on Society of Cannabis Clinicians.

]]> Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients https://www.cannabisclinicians.org/2022/11/12/medical-cannabis-use-and-inflammatory-cytokines-and-chemokines-among-adult-chronic-pain-patients/ Sat, 12 Nov 2022 13:43:57 +0000 https://www.cannabisclinicians.org/?p=27138 Utilizing cannabis as a therapeutic option for chronic pain (CP) has increased significantly. However, data regarding the potential immunomodulatory effects of cannabis in CP patients remain scarce. We aimed at exploring the relationship between cannabis use and inflammatory cytokines and chemokines among a cohort of CP patients

The post Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients appeared first on Society of Cannabis Clinicians.

]]> Medical marijuana knowledge and attitudes amongst internal medicine residents https://www.cannabisclinicians.org/2022/04/26/medical-marijuana-knowledge-and-attitudes-amongst-internal-medicine-residents/ Tue, 26 Apr 2022 22:15:58 +0000 https://www.cannabisclinicians.org/?p=26408 Mounting evidence suggests the safety and efficacy of medical marijuana (MM) in treating chronic ailments, including chronic pain, epilepsy, and anorexia. Despite incremental use of medical and recreational cannabinoids, current limited evidence shows generalized unpreparedness of medical providers to discuss or recommend these substances to their patients. Herein, the present study aims to examine internal medicine residents’ knowledge of marijuana and their attitude towards its medical use.

The post Medical marijuana knowledge and attitudes amongst internal medicine residents appeared first on Society of Cannabis Clinicians.

]]> A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope? https://www.cannabisclinicians.org/2021/11/17/a-systematic-review-of-fibromyalgia-and-recent-advancements-in-treatment-is-medicinal-cannabis-a-new-hope/ Thu, 18 Nov 2021 01:19:04 +0000 https://www.cannabisclinicians.org/?p=25191 Analysis of over 100 Cannabis samples quantified for terpene and cannabinoid content and genotyped for over 100,000 single nucleotide polymorphisms indicated that Sativa- and Indica-labelled samples were genetically indistinct on a genome-wide scale. Instead, we found that Cannabis labelling was associated with variation in a small number of terpenes whose concentrations are controlled by genetic variation at tandem arrays of terpene synthase genes.

The post A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope? appeared first on Society of Cannabis Clinicians.

]]>